IFNL1: A Potential Drug Target and Biomarker for the Treatment of Fibromyalgia

Target Name: IFNL1

NCBI ID: G282618

IFNL1

IFNL1: A Potential Drug Target and Biomarker for the Treatment of Fibromyalgia

Fibromyalgia is a chronic widespread pain condition that affects millions of people worldwide.1 It is characterized by widespread pain, stiffness, and fatigue, which can significantly impact an individual's quality of life.2 In addition to the physical symptoms, fibromyalgia often also involves psychological distress,3 which can further contribute to the overall impact of the condition.4 The exact cause of fibromyalgia is not known, but research has identified several potential underlying factors, including genetic,5 hormonal,6 and neurobiological mechanisms.7

One potential drug target for fibromyalgia is IFNL1, a protein that is expressed in the skin, joints, and other tissues.8 IFNL1 has been shown to play a role in the regulation of pain signaling and has been identified as a potential biomarker for fibromyalgia.9

In addition to its potential as a drug target, IFNL1 has also been shown to be a potential biomarker for fibromyalgia.10 Fibromyalgia patients often have reduced levels of IFNL1 in their skin samples, which could be an indicator of the underlying condition.11 Therefore, researchers are interested in using IFNL1 as a diagnostic tool and potential biomarker for fibromyalgia.12

IFNL1 has been shown to be involved in the regulation of pain signaling in various organisms, including mammals.13-15 In humans, IFNL1 has been shown to play a role in the regulation of pain signaling in the skin and has been shown to interact with other pain molecules, such as nociceptins and opioids.16-18 This suggests that IFNL1 may be a useful target for the treatment of fibromyalgia.

In addition to its potential as a drug target and biomarker, IFNL1 is also of interest as a potential therapeutic approach for fibromyalgia.19-21 IFNL1 has been shown to have potential therapeutic benefits in animal models of fibromyalgia,22 and may be a promising target for human clinical trials.23

In conclusion, IFNL1 is a potential drug target and biomarker for the treatment of fibromyalgia.24-27 Further research is needed to fully understand the role of IFNL1 in fibromyalgia and to develop safe and effective treatments for this chronic condition.28-30

Protein Name: Interferon Lambda 1

Functions: Cytokine with antiviral, antitumour and immunomodulatory activities. Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression

The "IFNL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFNL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets